Cargando…

Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients

The increasing use of technological devices for the management of diabetes is related to the prolonged exposure of patients’ skin to chemical and mechanical agents and, consequently, to the increased risk of developing dermatological complications. Among these, contact dermatitis is the most insidio...

Descripción completa

Detalles Bibliográficos
Autores principales: Passanisi, Stefano, Salzano, Giuseppina, Galletta, Francesca, Aramnejad, Sara, Caminiti, Lucia, Pajno, Giovanni B., Lombardo, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965381/
https://www.ncbi.nlm.nih.gov/pubmed/35370980
http://dx.doi.org/10.3389/fendo.2022.846137
_version_ 1784678420762853376
author Passanisi, Stefano
Salzano, Giuseppina
Galletta, Francesca
Aramnejad, Sara
Caminiti, Lucia
Pajno, Giovanni B.
Lombardo, Fortunato
author_facet Passanisi, Stefano
Salzano, Giuseppina
Galletta, Francesca
Aramnejad, Sara
Caminiti, Lucia
Pajno, Giovanni B.
Lombardo, Fortunato
author_sort Passanisi, Stefano
collection PubMed
description The increasing use of technological devices for the management of diabetes is related to the prolonged exposure of patients’ skin to chemical and mechanical agents and, consequently, to the increased risk of developing dermatological complications. Among these, contact dermatitis is the most insidious skin disorder. Despite the magnitude of the issue, no universally accepted recommendations on the management of this common complication are currently available. Our observational study aimed to describe all the solutions adopted by patients and their caregivers to treat and prevent the appearance of contact dermatitis and to describe the clinical impact of this cutaneous complication. Twenty-one pediatric patients (mean age 12.1 ± 3.7 years) with type 1 diabetes were recruited in the study. The most common treatment used to treat acute skin lesions was the application of topical corticosteroids, sometimes associated with topical antibiotics (9.5%). In order to prevent the further appearance of dermatitis, the most frequently adopted measure was the use of hydrocolloid and/or silicone-based adhesives, followed by the application of protective barrier films. One patient reported benefit from the off-label use of fluticasone propionate nasal spray. However, only 52.4% of the study participants achieved a definitive resolution of the skin issue, and 38.1% of patients were forced to discontinue insulin pump therapy and/or continuous glucose monitoring. No differences were observed in glycated hemoglobin values between the period before and after the onset of contact dermatitis. Our study confirms the severity of this dermatological complication that may hinder the spread of new technologies for the management of diabetes. Finally, our findings highlight the importance of establishing close collaboration both with pediatric allergy specialists to prescribe the most suitable treatment and with manufacturing companies to ensure that adhesives of technological devices are free of harmful well-known sensitizers.
format Online
Article
Text
id pubmed-8965381
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89653812022-03-31 Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients Passanisi, Stefano Salzano, Giuseppina Galletta, Francesca Aramnejad, Sara Caminiti, Lucia Pajno, Giovanni B. Lombardo, Fortunato Front Endocrinol (Lausanne) Endocrinology The increasing use of technological devices for the management of diabetes is related to the prolonged exposure of patients’ skin to chemical and mechanical agents and, consequently, to the increased risk of developing dermatological complications. Among these, contact dermatitis is the most insidious skin disorder. Despite the magnitude of the issue, no universally accepted recommendations on the management of this common complication are currently available. Our observational study aimed to describe all the solutions adopted by patients and their caregivers to treat and prevent the appearance of contact dermatitis and to describe the clinical impact of this cutaneous complication. Twenty-one pediatric patients (mean age 12.1 ± 3.7 years) with type 1 diabetes were recruited in the study. The most common treatment used to treat acute skin lesions was the application of topical corticosteroids, sometimes associated with topical antibiotics (9.5%). In order to prevent the further appearance of dermatitis, the most frequently adopted measure was the use of hydrocolloid and/or silicone-based adhesives, followed by the application of protective barrier films. One patient reported benefit from the off-label use of fluticasone propionate nasal spray. However, only 52.4% of the study participants achieved a definitive resolution of the skin issue, and 38.1% of patients were forced to discontinue insulin pump therapy and/or continuous glucose monitoring. No differences were observed in glycated hemoglobin values between the period before and after the onset of contact dermatitis. Our study confirms the severity of this dermatological complication that may hinder the spread of new technologies for the management of diabetes. Finally, our findings highlight the importance of establishing close collaboration both with pediatric allergy specialists to prescribe the most suitable treatment and with manufacturing companies to ensure that adhesives of technological devices are free of harmful well-known sensitizers. Frontiers Media S.A. 2022-03-15 /pmc/articles/PMC8965381/ /pubmed/35370980 http://dx.doi.org/10.3389/fendo.2022.846137 Text en Copyright © 2022 Passanisi, Salzano, Galletta, Aramnejad, Caminiti, Pajno and Lombardo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Passanisi, Stefano
Salzano, Giuseppina
Galletta, Francesca
Aramnejad, Sara
Caminiti, Lucia
Pajno, Giovanni B.
Lombardo, Fortunato
Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
title Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
title_full Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
title_fullStr Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
title_full_unstemmed Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
title_short Technologies for Type 1 Diabetes and Contact Dermatitis: Therapeutic Tools and Clinical Outcomes in a Cohort of Pediatric Patients
title_sort technologies for type 1 diabetes and contact dermatitis: therapeutic tools and clinical outcomes in a cohort of pediatric patients
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965381/
https://www.ncbi.nlm.nih.gov/pubmed/35370980
http://dx.doi.org/10.3389/fendo.2022.846137
work_keys_str_mv AT passanisistefano technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients
AT salzanogiuseppina technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients
AT gallettafrancesca technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients
AT aramnejadsara technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients
AT caminitilucia technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients
AT pajnogiovannib technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients
AT lombardofortunato technologiesfortype1diabetesandcontactdermatitistherapeutictoolsandclinicaloutcomesinacohortofpediatricpatients